Loop diuretics remain a fundamental pharmacological therapy to remove excess fluid and improve symptom control in acute decompensated heart failure. Several recent randomised controlled trials have examined the clinical benefit of continuous vs. bolus furosemide in acute decompensated heart failure, but have reported conflicting findings. The aim of this review was to compare the effects of continuous and bolus furosemide with regard to mortality, length of hospital stay and its efficacy profile in acute decompensated heart failure. All parallel-arm randomised controlled trials from MEDLINE, EMBASE, PubMed and the Cochrane Database of Systematic Reviews from inception until May 2017 were included. Cross-over randomised controlled trials, observational studies, case reports, case series and nonsystematic reviews that involved children were excluded. Eight trials (n = 669) were eligible for inclusion. There was no difference between furosemide continuous infusion and bolus administration for all-cause mortality (four studies; n = 491; I 2 = 0%; OR 1.65; 95%CI 0.93-2.91; p = 0.08) or duration of hospitalisation (six studies; n = 576; I 2 = 71%; mean difference 0.27; 95%CI À1.35 to 1.89 days; p = 0.74). Continuous infusion of intravenous furosemide was associated with increased weight reduction (five studies; n = 516; I 2 = 0%; mean difference 0.70; 95%CI 0.12-1.28 kg; p = 0.02); increased total urine output in 24 h (four studies; n = 390; I 2 = 33%; mean difference 461.5; 95%CI 133.7-789.4 ml; p < 0.01); and reduced brain natriuretic peptide (two studies; n = 390; I 2 = 0%; mean difference 399.5; 95%CI 152.7-646.3 ng.l À1 ; p < 0.01), compared with the bolus group. There was no difference in the incidence of raised creatinine and hypokalaemia between the two groups. In summary, there was no difference between continuous infusion and bolus of furosemide for all-cause mortality, length of hospital stay and electrolyte disturbance, but continuous infusion was superior to bolus administration with regard to diuretic effect and reduction in brain natriuretic peptide.
Introduction
Heart failure is a common, multifactorial, complex clinical syndrome in an ageing population, that contributes to significant morbidity and mortality worldwide [1, 2] . This chronic condition incurs huge financial costs to healthcare systems in emergency medical admissions, re-admissions and prolonged hospital stay [3, 4] .
Fluid retention is a classic effect of heart failure that results from impaired cardiac contraction [5] . In current practice, loop diuretics (especially furosemide) remain a fundamental pharmacological treatment in acute decompensated heart failure, reducing lung water and improving oxygenation by promoting diuresis [1, 6] . Despite the recommended use of intravenous (i.v.) loop diuretics in clinical guidelines, there is no general consensus with regard to administration mode or dosage in the heart failure population. This is at the discretion of physicians, which varies across medical centres and countries [7] . Injudicious use of diuretics could potentially harm patients by causing renal impairment, electrolyte imbalance and hemodynamic instability, which may in turn increase duration of hospitalisation and contribute to worse prognosis [8, 9] .
Several recent randomised controlled trials (RCTs) have investigated the efficacy and safety profiles of modes of administration (continuous infusion vs. bolus) of i.v. furosemide in heart failure populations, but results have been conflicting [5, 7, [10] [11] [12] [13] [14] [15] [16] . Continuous infusion of furosemide is believed to confer additional benefits over bolus injection, with less variability in peak plasma furosemide concentration resulting in a consistent, predictable urine output and less risk of electrolyte disturbance. In addition, a few studies have reported that continuous infusion correlated with lower mortality rate and shorter hospital stay compared with bolus administration [14, 17] . However, the largest multi-centre RCT comparison, conducted by Felker et al. [7] found no significant difference in mortality and other clinical end-points between continuous infusion or bolus injection of furosemide in heart failure. Several recent trials have suggested a higher incidence of potentially harmful effects with continuous infusions, namely transient hypotension, electrolyte disturbance and acute kidney injury [7, 10, [13] [14] [15] 17] .
Thus, it remains unclear whether one method of furosemide administration is superior to the other in the heart failure population. We performed a systematic review and meta-analysis of parallel-arm RCTs to compare i.v. continuous infusion of furosemide with bolus administration, with regard to mortality, hospital stay, diuresis and adverse effects.
Methods
This review was conducted and reported according to the 'Preferred Reporting Items for Systematic Review and Meta-analysis' (PRISMA) statement 2015 [18] . The research questions were formulated using a population, intervention, control, outcomes (PICO) approach (see also Supporting Information, Table S1 ).
Ovid MEDLINE, EMBASE, PubMed and the Cochrane Database of Systematic Reviews were searched from inception until May 2017 for RCTs, comparing both continuous infusion and intermittent bolus injection of furosemide in heart failure. The search strategy and terms used are provided in the Supporting Information (Table S2) . Publications not written in the English language were excluded. The bibliographies of included papers and relevant systematic reviews were hand-searched for additional papers. Experts and authors of papers identified in the search strategy were contacted for additional data as required.
Primary outcomes were all-cause mortality and hospital stay. Pre-specified secondary outcomes were changes in serum creatinine; changes in weight loss; and incidence of raised creatinine and hypokalaemia during the duration of treatment. Other relevant outcomes were considered for the meta-analysis if they were measured in more than one of the included studies. On this basis, reduction of brain natriuretic peptide (BNP) and increase in urine output at 24 h and 72 h were also included.
Titles and abstracts were independently screened against eligibility criteria by two authors (KN and JY). The same two reviewers independently screened full texts of qualifying papers. Both reviewers resolved disagreements at all stages. Inclusion criteria were parallelarm clinical trials, systematic reviews or meta-analyses that compared effects of i.v. continuous infusion and boluses of furosemide on the outcomes of mortality, length of hospital stay, changes of serum electrolytes, total urine output, changes in body weight loss and BNP reduction in the heart failure population.
Observational studies, case reports, case series and non-systematic reviews were excluded. All cross-over studies were excluded in this systematic review in order to minimise risk of bias due to inadequate washout period of furosemide before switching mode of administration [19] [20] [21] [22] [23] [24] . Studies involving congenital heart disease, valvular heart disease, post-cardiac surgical patients and patients less than 16 years of age were also excluded. All the included RCTs were assessed for risk of bias using the Cochrane Collaboration risk of bias assessment tool (https://handbook.cochrane.org). In addition to measures of outcomes, citation, year of publication, study design, country, population, sample size and daily dose of furosemide were also extracted.
Statistical analyses were undertaken using RevMan Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). Analysis of funnel plots for all primary and secondary outcomes was not undertaken, as there were less than 10 studies for each measured outcome to assess the risk of publication bias. The I 2 test was used to assess the heterogeneity of studies. Values of 0.25, 0.50 and 0.75 were used to determine low, moderate and high heterogeneity, respectively. A p value of < 0.05 was considered to denote statistical significance of heterogeneity. In line with standard methodology (https://handb ook.cochrane.org), if no significant heterogeneity was noted, a fixed effects model (FEM) analysis (MantelHaenszel method) was used to pool estimates. If evidence of significant heterogeneity was observed, a random-effects model (REM) analysis (DerSimonianLaird) method was used.
Results
The results of the literature search and study selection process are outlined in the PRISMA flow chart (Fig. 1) . The titles and abstracts of 3624 non-duplicate articles were screened, of which 31 articles were retrieved. After applying inclusion and exclusion criteria, eight parallel-arm RCTs with a total of 669 subjects were included in this meta-analysis. Details of the excluded studies are outlined in the Supporting Information (Table S3 ).
The clinical characteristics of all included RCTs comparing the outcomes of continuous infusion and bolus injection of furosemide in heart failure are presented in Table 1 . Out of the eight studies, three studies were double-blind [7, 13, 16] , two studies were singleblind [11, 14] , two studies were unblinded [10, 15] and one study [12] was rated as 'unclear' due to insufficient information given in the manuscript. Two studies were of the heart failure population in intensive care [12, 14] , one study was of the heart failure population in the emergency department [11] , and the rest of the included studies [7, 10, 13, 15, 16] were of the heart failure population in hospital wards. Overall, the majority of the included studies [7, 10, 12, 13, 15, 16] had low risk of bias, with the exception of two studies [11, 14] in which all patients received a bolus injection of furosemide 40 mg before random allocation to either continuous infusion or intermittent bolus injection of furosemide (see also Supporting Information, Table S4 ). No studies were commercially sponsored, and there were no conflicts of interest, so no studies were excluded on this basis.
Four studies [7, 10, 13, 14] compared all-cause mortality within six months, with a total of 491 patients who received either continuous infusion or intermittent bolus injection of furosemide. Statistical heterogeneity was assessed as low in pooled effect. There was no effect on mortality rate (I 2 = 0%; OR 1.65; 95%CI 0.93-2.91; p = 0.08, Fig. 2a ). There was also no difference in mortality rate between the two groups in a secondary analysis excluding ICU patients [14] (three studies; n = 431; I 2 = 0%; OR 1.78; 95%CI 0.99-3.21; p = 0.05, Fig. 2b ). Six RCTs [7, 10, [13] [14] [15] [16] examined duration of hospital stay, a total of 576 patients. We found no difference in the duration of hospitalisation between the continuous infusion and intermittent bolus groups (I 2 = 71%; mean difference 0.27; 95%CI 1.35-1.89 days; p = 0.74, Fig. 3 ). Statistical heterogeneity was assessed as moderate across studies. Five studies [7, 10, 13, 15, 16] measured changes in weight loss as a surrogate outcome of diuretic effect between both groups at the end of randomisation, a total of 516 patients. Continuous infusion of furosemide resulted in a reduction in body weight compared with intermittent bolus administration (I 2 = 0%; mean difference 0.70; 95%CI 0.12-1.28 kg; p = 0.02, Fig. 4 ). The test of heterogeneity was low in pooled effect. Four studies [7, 10, 13, 16] investigated changes in plasma creatinine at discharge or 72 h, whichever came first (total of 460 patients). Statistical heterogeneity was assessed as high. There was no difference in plasma creatinine changes between patients who received either continuous infusion or intermittent bolus injection of furosemide (I 2 = 99%; mean difference 0.46; 95%CI 0.25-1.17 mg.dl À1 ; p = 0.20; see also Supporting Information, Fig. S1 ). When considering plasma creatinine increases > 0.3 mg.dl
À1
, three studies [7, 11, 15 ] with a total of 430 patients showed no differences between groups (I 2 = 0%; mean difference 1.16; 95%CI 0.7-1.9
mg.dl
; p = 0.57; see also Supporting Information, Fig. S2 ). No significant heterogeneity was found across studies. The incidence of hypokalaemia at Day 3 or at discharge was reported in three studies [7, 10, 11] ; p = 0.97; see also Supporting Information, Fig. S3 ).
Five studies [11] [12] [13] [14] [15] investigated total urine output in the first 24 h after random allocation of patients into either continuous or bolus i.v. furosemide groups. We found no difference between these two groups (I 2 = 80%; mean difference 311.61; 95%CI 153.71-776.93 ml; p = 0.19, Fig. 5a ). The high heterogeneity was statistically significant in all the included studies. 
articles included
Inclusion/exclusion criteria applied Inclusion/exclusion criteria applied Figure 1 PRISMA flow diagram of study selection process. RCT, randomised controlled trial; ADHF, acute decompensated heart failure; ICU, intensive care unit; BNP, brain natriuretic peptide.
A secondary analysis was performed excluding Shah et al.'s study [14] due to the high risk of bias. We found that continuous infusion was associated with an increase in total urine output for the first 24 h compared with the bolus group (I 2 = 33%; mean difference 461.54; 95%CI 133.67-789.41 ml; p < 0.01, Fig. 5b) , with non-significant heterogeneity. Only two RCTs [7, 10] reviewed diuretic effect by measuring total urine output in 72 h, a total of 349 patients. There was no significant difference in À663.02 to 589.88 ml; p = 0.91, Fig. 4c ). No significant heterogeneity was found among these studies.
In two studies with a total of 390 patients that reported changes in BNP [7, 13] ; p < 0.01, Fig. 6 ). No significant heterogeneity was detected for pooled effect.
Discussion
To our knowledge, this is the first meta-analysis which only included parallel-arm RCTs and BNP for data analysis. Our main finding was that, regarding allcause mortality or duration of hospitalisation for mg.dl
À1
, there was no difference between patients treated with continuous i.v. infusion of furosemide or intermittent boluses. Continuous infusion was associated with greater weight loss, increased total urine output in 24 h and BNP reduction when compared with intermittent bolus. We did not observe any differences in plasma creatinine at Day 3 or at discharge, incidence of raised creatinine, incidence of hypokalaemia or total urine output in 72 h in either group.
All loop diuretics have to be filtered and secreted in the luminal side of the loop of Henle to exert a diuretic effect and reduce fluid overload [25] . In theory, continuous infusion of loop diuretics is associated with a more consistent plasma drug concentration, ensuring a more predictable diuretic effect and minimising the risk of diuretic resistance [25, 26] . An infusion is also associated with lower peak drug concentrations compared with bolus injection, and lower incidences of neurohormonal activation, electrolyte imbalance and impaired renal function [26] . Despite all these aforementioned theoretical advantages, we failed to find any clinical benefits associated with the use of continuous infusion compared with bolus i.v. furosemide, as measured by all-cause mortality and duration of hospitalisation.
In our analysis of all four parallel-arm RCTs on allcause mortality, three [7, 10, 13] reported higher mortality rate for continuous infusion in a hospitalised heart failure population, while one [14] reported higher mortality rate for bolus administration in an ICU population. However, our review suggested no difference in mortality between the two groups. We also carried out a secondary analysis to exclude ICU patients, as they tend to be more vulnerable and sicker, with a higher incidence of multi-organ failure compared to other hospital patients. Results were similar to the main analysis, with no difference in mortality between groups [14] . Our primary and secondary findings did not agree with a metaanalysis of eight cross-over RCTs by Salvador et al. in 2005 , where it was concluded that continuous infusion was superior to bolus, with a lower mortality rate [27] . Their conclusions have to be interpreted with caution, as all their included RCTs were cross-over designs with potential biases of inadequate wash-out periods and small sample sizes [27] .
Our meta-analyses with three additional RCTs in 2014 and 2015 indicated no difference in duration of hospital stay between continuous infusion and bolus groups, which corresponded with the findings of a review conducted by Wu et al. in 2014 [28] . However, several studies have reported that continuous infusion was associated with shorter hospital stay, lesser adverse effects and more rapid achievement of therapeutic diuresis [27, 29] . Howard et al. have suggested continuous infusion as a safe and cost-effective therapy, reducing length of hospital stay in elderly patients with heart failure [29] . Given the high heterogeneity of our forest plot analysis, many confounding factors such as age, comorbidities, small sample size and concurrent medications may have influenced hospital stay in all six included RCTs. Also, we were unable to control or adjust for those factors at review level, so this finding needs to be interpreted with caution.
Greater body weight loss following furosemide administration has been found to be associated with improved outcomes [28] . Our meta-analysis demonstrated that continuous infusion of furosemide was associated with greater body weight loss when compared with bolus administration (p = 0.02). However, this finding corresponded to a non-significant difference in total urine output over 72 h between the two groups, potentially risking diuretic resistance where increasing doses of diuretic are needed to maintain therapeutic effect. We believe that body weight may be a better surrogate measure for diuretic effect than total urine output, as not all patients were catheterised to ensure accurate measurement and recording. There was potential reporting bias, as observed in a RCT by Shah et al. in 2014 [14] . All patients selfreported their urine output, and only those who were unable to pass urine were catheterised for urine measurement; the mean total urine output in 24 h measured in this study was significantly lower compared with other studies. In a secondary analysis excluding Shah et al.'s study, we found that continuous infusion was associated with significantly higher total urine output in 24 h in comparison with bolus administration (p < 0.01). This may be explained by the fact that peak effects of bolus administration are achieved in the first 1-2 h by rapidly increasing sodium excretion, which then declines progressively over time [30] . A consistent plasma drug concentration of furosemide from continuous infusion may have a more consistent diuretic effect, producing greater weight reduction and total urine output in 24 h than following bolus administration. In addition, different dosages of i.v. furosemide were used while comparing groups across all studies, which could also influence the comparative total urine output and weight loss.
Brain natriuretic peptide is a hormone that is released from the ventricular wall of the heart in response to volume expansion and possible increased wall stress [31] . Reductions in BNP, especially more than 30% from initial admission levels, are associated with improved short-and long-term clinical outcomes [32] . It is believed that consistent plasma diuretic concentrations resulting from continuous infusion suppresses neuro-humoral activation, rebound water and sodium re-absorption and vasoconstriction of efferent renal arterioles, resulting in better diuretic effect. It may also result in greater BNP reduction [33] . This new biomarker has been used in recent studies to examine correlation with the clinical outcomes of heart failure patients, randomly allocated to either continuous or bolus i.v. furosemide [7, 13] . In our meta-analysis, we found that continuous infusion was superior to intermittent bolus in terms of reduction in BNP, but it did not correlate with our primary outcomes of allcause mortality and hospital stay. A potential confounding factor to the BNP changes could be different diuretic doses administrated in these two RCTs [7, 13] .
Acute kidney injury with raised creatinine and hypokalaemia are frequent adverse effects of loop diuretics. In this review, we found no significant difference between continuous infusion and bolus administration of i.v. furosemide in the incidence of these effects, which corresponded with the findings of all previous meta-analysis [27, 28, 34] . Despite this, careful monitoring of electrolyte imbalance and kidney function during the administration of loop diuretics in heart failure is still recommended to allow early detection and correction of abnormalities [28] .
A strength of this review is that it represented a comprehensive up-to-date analysis of studies investigating the effects of continuous vs. bolus injection of furosemide on mortality, length of hospital stay and other clinical outcomes in the heart failure population. An exhaustive literature search was carried out. Authors of all the included RCTs were contacted, and some were able to make their data available to us [10, 16] . All included parallel-arm RCTs were subjected to a rigorous assessment of methodological quality. Two previous syntheses of such evidence were conducted in 2014 (which included some cross-over RCTs), and many of them were ranked as unclear for methodological quality assessment [28, 34] . Our current analysis included only parallel-arm RCTs, and we have added four further well-conducted RCTs [11, 13, 14, 16] . Also, this was the first review to examine the use of BNP in heart failure, which was only measured in recent studies [7, 13] . Our meta-analysis provides an estimate of important outcomes across these studies, and it should be useful to inform future practice in the management of heart failure.
Limitations of this study are common to other meta-analyses of RCTs, namely differences in population characteristics, small patient numbers, differing diuretic dosages and schedules of administration, uses of concomitant drugs and varied primary outcomes. Allen et al. studied younger patients [10] . Unfortunately, we were unable to control for confounding factors in all included RCTs at this review level. All these differences may have contributed to the high heterogeneity of some measured variables in our review. Despite evidence of low statistical heterogeneity in some of the assessed clinical outcomes, our pooled estimates were unadjusted and so should be interpreted with caution.
In summary, in this meta-analysis of eight parallel-arm RCTs, continuous infusion of furosemide appeared to have better diuretic effects than bolus administration, as assessed by greater weight loss, increased total urine output in the first 24 h and reduction in BNP. There were no differences between administration methods with regard to mortality, duration of hospitalisation, or the adverse effects of raised creatinine and hypokalaemia.
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